HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2601 Amivantamab (Anti-HGFR / c-Met) Amivantamab (Anti-HGFR / c-Met) is a human bispecific antibody targeting EGFR-MET.It has immune anticancer activity in non-small cell lung cancer (NSCLC). MW :146.1 KD. Oct 11 2023
A2857 Anti-Sphingosine-1-phosphate Anti-Sphingosine-1-phosphate is a human IgG1 monoclonal anti-Sphingosine-1-phosphate antibody that targets lysosphingolipids, thereby lowering the concentration of S1P in the extracellular fluid. MW: 145.74 KD. Oct 11 2023
A3116 Anti-GLP1R Anti-GLP1R is a humanized antibody targeting GLP-1 receptor (GLP-1R). It can be used in therapy for type 2 diabetes mellitus. MW : 144.5 KD. Oct 11 2023
A3123 Setoxaximab (Anti-Shiga toxin (E.coli)) Setoxaximab (Anti-Shiga toxin (E.coli)) is a mouse chimeric IgG1(kappa) antiboy that target shiga toxin 1 and shiga toxin 2, produced by E. coli. It can be used in the treatment of hemolytic-uremic syndrome (HUS). MW :147.08 KD. Oct 11 2023
A2615 Anti-PMEL Anti-PMEL is a monoclonal antibody targeting human PMEL protein. It is used as a target for antibody drug conjugate (ADC) therapy in melanoma. MW :145.38 KD. Oct 11 2023
A2873 Anti-ICAM3 / CD50 Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD. Oct 11 2023
A2874 Anti-MUC17 Anti-MUC17 is an IgG1 monoclonal antibody against MUC17, a membrane-bound protein highly expressed on the surface of intestinal cells. MW: 146.66 KD. Oct 11 2023
A2875 Anti-TEM7R / PLXDC2 Anti-TEM7R / PLXDC2 is a humanized IgG1 monoclonal antibody against PLXDC1 (tumor endothelial marker 7 or TEM7), a cell-surface receptor for PEDF, with anti-tumor activity. MW: 143.94 KD. Oct 11 2023
A2627 Anti-Complement C5aR1 (G2_anti-C5aR) Anti-Complement C5aR1 (G2_anti-C5aR) is a rat monoclonal antibody that detects Complement 5a receptor (C5aR). It exhibit potent proinflammatory stimulus with immunomodulatory activities. MW :146.08 KD. Oct 11 2023
A2633 Anti-OX2R / CD200R1 Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD. Oct 11 2023
E4265 Pyrimidine Pyrimidine is an endogenous metabolite. It is used to study the photoinduced ion chemistry of the halogenated pyrimidines, a class of prototype radiosensitizing molecules, and is also used to assess pyrimidine/purine asymmetry quantitatively. Oct 11 2023
D4060 Mirvetuximab-MMAE Mirvetuximab-MMAE is an ADC targeting FOLR1 (folate receptor 1). It can be used in ovarian and other FRα-positive cancer research. MW :145.96 KD. Oct 11 2023
D4061 Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) is an ADC targeting GPC3 (glypican-3). It induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth and can be used in the research of hepatocellular carcinoma (HCC). MW :145.58 KD. Oct 11 2023
A2640 Anti-CHI3L1 Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD. Oct 11 2023
D4062 Anti-KAAG1 (ADCT-901-MMAE) Anti-KAAG1 (ADCT-901-MMAE) is an ADC composed of a humanized monoclonal antibody (3A4) targeting human KAAG1. It is used for the treatment of advanced solid tumors including platinum resistant ovarian cancer and triple negative breast cancer. MW :145.28 KD. Oct 11 2023
A2642 Zolbetuximab (Anti-CLDN18.2) Zolbetuximab (Anti-CLDN18.2) is a monoclonal antibody targeting Claudin-18.2. It can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. MW :150 KD. Oct 11 2023
A3154 Anti-CDH17 / Cadherin-17 (10C12) Anti-CDH17 / Cadherin-17 (10C12) is a humanized monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on liver and stomach tumour cells. It can be used as therapeutics for treating lung metastasis of hepatocellular carcinoma (HCC). MW :143.68 KD. Oct 11 2023
A2643 Anti-CLDN6 (IMAB027) Anti-CLDN6 (IMAB027) is a fully humanized antibody targeting CLDN6. It gets conjugated to monomethyl auristatin E( MMAE) resulting in the potential therapeutic CLDN6–23-ADC. It exhibits antitumor efficacy in ovarian epithelial carcinomas.MW :144.42 KD. Oct 11 2023
A2899 Margetuximab (Anti-ERBB2 / HER2 / CD340) Margetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD. Oct 11 2023
A3155 Anti-CDH17 / Cadherin-17 (PTA001_A4) Anti-CDH17 / Cadherin-17 (PTA001_A4) is a humanized monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on tumour cells. It can be used as therapeutics for treating various cancers, including colorectal cancer. MW :149.12 KD. Oct 11 2023